---
title: 'Stem cell collection after lenalidomide, bortezomib and dexamethasone plus
  elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single
  centre experience from the GMMG-HD6 and -HD7 trials'
date: '2023-11-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37990162/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231122170715&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This study demonstrates that stem cell collection is feasible
  after prolonged induction with isatuximab-RVd without collection failures and might
  be further explored as induction ...'
disable_comments: true
---
CONCLUSIONS: This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction ...